BNP Paribas Financial Markets Decreases Stock Holdings in BioNTech SE Sponsored ADR $BNTX

BNP Paribas Financial Markets lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 13.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,103,298 shares of the company’s stock after selling 172,177 shares during the quarter. BNP Paribas Financial Markets’ holdings in BioNTech were worth $108,807,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Dodge & Cox bought a new position in BioNTech during the second quarter valued at approximately $93,421,000. Franklin Resources Inc. raised its stake in BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after buying an additional 326,556 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of BioNTech by 5.6% during the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after buying an additional 35,958 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of BioNTech by 2.8% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 667,635 shares of the company’s stock worth $71,083,000 after buying an additional 18,351 shares during the last quarter. Finally, Candriam S.C.A. grew its holdings in shares of BioNTech by 0.5% in the third quarter. Candriam S.C.A. now owns 589,452 shares of the company’s stock worth $58,132,000 after acquiring an additional 2,716 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Performance

BNTX opened at $90.10 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.54. The stock has a market capitalization of $20.29 billion, a price-to-earnings ratio of -17.19 and a beta of 1.51. The company has a fifty day moving average of $106.54 and a 200 day moving average of $102.66. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

Analyst Ratings Changes

A number of research firms have weighed in on BNTX. TD Cowen lowered their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a report on Wednesday. UBS Group upgraded shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a research report on Monday, February 2nd. Jefferies Financial Group reduced their target price on shares of BioNTech from $151.00 to $138.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Bank of America reiterated a “buy” rating and set a $128.00 price target on shares of BioNTech in a research note on Tuesday. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average target price of $133.73.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.